Real-World Data on First-Line Treatment of Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer in Brazil (BRAVE Study)
Clinical Breast Cancer · 2025-12 · 25 (8) · e1040-e1049
DOI: 10.1016/j.clbc.2025.05.020 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Breast Cancer, 2025-12. Verfasst von Gustavo Werutsky und 21 weiteren Autor:innen. Beteiligte Einrichtung: Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil. Electronic address: gustavo.werutsky@lacogcancerresearch.org. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Agents, Hormonal. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis, Novartis Pharmaceuticals Corporation, SAS Institute.
Abstract (Originalsprache)
INTRODUCTION: Endocrine therapy (ET) plus CDK4/6 inhibitors has become the standard first-line therapy for hormone receptor-positive/HER2-negative metastatic breast cancer (MBC). Utilizing real-world data, we aimed to characterize treatment patterns, assess the impact of health insurance type, and evaluate outcomes among Brazilian MBC patients with this subtype treated in the first-line setting. PATIENTS AND METHODS: This is an observational retrospective study assessing female patients aged ≥ 18 years diagnosed with HR+/HER2- MBC between January/2018 and December/2020 at 13 sites in Brazil. The primary objective was to describe the treatment patterns within both the public and private healthcare systems. Secondary outcomes were progression-free survival (PFS) and overall survival (OS). RESULTS: In total, 307 patients were included. The most frequent treatment was ET alone (42.4%), followed by chemotherapy (31.6%), and ET plus CDK4/6 inhibitors (25.1%). The greatest difference in access to treatment was observed in the use of ET plus CDK4/6 inhibitors between the private (48.3%) and public healthcare systems (2.6%), (P < .0001). Of the 84 patients that received CDK4/6 inhibitors, ribociclib was the most used (56.0%). With a median follow-up of 32.2 months (95% CI, 29.4-34.4), the median progression-free survival (PFS) was 24.2 months (95% CI, 18.6-30.4) in the public and 23.80 months (95% CI, 18.3-34.2) in the private healthcare system (P = .9294). The median OS was 52.7 months (95% CI, 49.4-NR) in the overall population. CONCLUSION: ET remains the most used first-line treatment in Brazil. However, access to therapies varies significantly between public and private healthcare sectors. This disparity highlights inequality in access to treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil. Electronic address: gustavo.werutsky@lacogcancerresearch.org.
- Serviço de Oncologia, Hospital Moinhos de Vento (HMV), Porto Alegre, Brazil.
- Centro de Pesquisa da Serra Gaúcha (CEPESG), Caxias do Sul, Brazil; Grupo Brasileiro de Estudos em Câncer de Mama (GBECAM), Porto Alegre, Brazil.
- Dasa Institute for Education and Research (IEPD), Brasília, Brazil; Dasa Oncology/Hospital Brasilia, Brasília, Brazil.
- Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; Centro Universitário UNIFOA, Volta Redonda, Brazil; Instituto Projeto Cura, São Paulo, Brazil.
- Centro Integrado de Pesquisa da Amazônia (CINPAM), Manaus, Amazonas, Brazil.
Förderung
- Novartis
- Novartis Pharmaceuticals Corporation
- SAS Institute
Zitieren
APA
Werutsky, G., Rosa, D. D., Reinert, T., Barroso-Sousa, R., Resende, H., Signorini, P., Cronemberger, E., Fagundes, J. G. M., Leal, J. H. S., Guimarães, M. B., Vieira, A., Weis, L. N., de Figueiredo, J. M. B., Correa, T. S., Venero, F. C., Pauletto, M. M., Franche, L. M. T., Bernardes, M. M., de Oliveira, A. H. O., …, & Bines, J. (2025). Real-World Data on First-Line Treatment of Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer in Brazil (BRAVE Study). Clinical Breast Cancer, 25(8), e1040-e1049. https://doi.org/10.1016/j.clbc.2025.05.020
Vancouver
Werutsky G, Rosa DD, Reinert T, Barroso-Sousa R, Resende H, Signorini P, et al. Real-World Data on First-Line Treatment of Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer in Brazil (BRAVE Study). Clinical Breast Cancer. 2025;25(8):e1040-e1049. doi:10.1016/j.clbc.2025.05.020
BibTeX
@article{Werutsky2025,
author = {Werutsky, Gustavo and Rosa, Daniela Dornelles and Reinert, Tomás and Barroso-Sousa, Romualdo and Resende, Heloísa and Signorini, Poliana and Cronemberger, Eduardo and Fagundes, Juliana Góes Martins and Leal, Jorge Henrique Santos and Guimarães, Marina Bachmann and Vieira, Aline and Weis, Luiza Nardin and de Figueiredo, José Márcio Barros and Correa, Tatiana Strava and Venero, Fernando Castilho and Pauletto, Maiane Maria and Franche, Luísa Mostardeiro Tabajara and Bernardes, Marina Musse and de Oliveira, André Henrique Ornelas and de Jesus, Rafaela Gomes and Gössling, Gustavo and Bines, José},
title = {Real-World Data on First-Line Treatment of Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer in Brazil (BRAVE Study)},
journal = {Clinical Breast Cancer},
year = {2025},
volume = {25},
number = {8},
pages = {e1040--e1049},
doi = {10.1016/j.clbc.2025.05.020}
}
EUVIMED